DOCSLIB.ORG

The Effect of Rofecoxib and Diclofenac on Blood Picture in Male Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effect of Rofecoxib and Diclofenac on Blood Picture in Male Patients ٢٠٠٨ ,١.No ,٨&٧ .Irq J Pharm Vol The effect of rofecoxib and diclofenac on blood picture in male patients Mohammed Z.K. Al-Hayali*, Faris A. Ahmed. ** *Directorate of Health, Mosul. **Department of physiology, Ninevah college of Medicine University of Mosul. Received: Accepted ٧.١.٢٠٠٨ ١٠.١٠.٢٠٠٧ ABSTRAT Objectives: To assess the effect of roficoxib and also the effect of diclofenac as a standard nonsteroidal anti-inflammatory drug (NSAD) on complete blood picture. mg/day ٢٥ male patients on roficoxib therapy at ٢٩ Methods: Complete blood picture was taken for male patients on roficoxib ١٥ consecutive days. Complete blood picture was also taken for ٢١-١٤ for consecutive days. Comparison was made between measurements ٢١-١٤ mg/day for ١٠٠ thearapy at of blood picture before and at the end of treatment by using Students paired t-test. Results: Roficoxib or diclofenac showed no significant changes in complete blood picture in the male patients in comparison with the measurements before treatment. Conclusion: Roficoxib or diclofenac has no significant effect on blood picture in patients when used for short term with moderate doses. Keywords: roficoxib, diclofenc, complete blood picture. اﻟﺨﻼﺻﺔ ﻣﻘﺪﻣﺔ: ﻟﺪراﺳﺔ ﺗﺎﺛﻴﺮ ﻋﻘﺎر روﻓﻴﻜﻮآﺴﺐ ﻋﻠﻰ ﻓﺤﻮﺻﺎت اﻟﺪم اﻟﻜﺎﻣﻠﺔ آﺬﻟﻚ ﻟﺪراﺳﺔ ﺗﺎﺛﻴﺮ ﻋﻘﺎرداﻳﻜﻠﻮﻓﻴﻨﺎك آﻌﻘﺎر ﻗﻴﺎﺳﻲ ﻏﻴﺮ ﺳﺘﻴﺮودي ﻣﻀﺎد ﻟﻼﻟﺘﻬﺎﺑﺎت ﻋﻠﻰ ﻓﺤﻮﺻﺎت اﻟﺪم اﻟﻜﺎﻣﻠﺔ. اﻟﻄﺮق: اﺧﺬت ﻓﺤﻮﺻﺎت اﻟﺪم اﻟﻜﺎﻣﻠﺔ ﻟﺘﺴﻌﺔ وﻋﺸﺮﻳﻦ ﻣﺮﻳﺾ ﻣﻦ اﻟﺬآﻮر وﺗﺤﺖ ﻋﻼج روﻓﻴﻜﻮآﺴﺐ ﺑﺠﺮﻋﺔ ٢٥ ﻣﻠﻐﻢ ﻓﻲ اﻟﻴﻮم ﻟﻔﺘﺮة ١٤ -٢١ ﻳﻮم ﺑﺼﻮرة ﻣﺘﺘﺎﻟﻴﺔ. آﺬﻟﻚ اﺧﺬت ﻓﺤﻮﺻﺎت اﻟﺪم اﻟﻜﺎﻣﻠﺔ ﻟﺨﻤﺴﺔ ﻋﺸﺮ ﻣﺮﻳﺾ ﻣﻦ اﻟﺬآﻮر وﺗﺤﺖ ﻋﻼج داﻳﻜﻠﻮﻓﻴﻨﺎك ﺑﺠﺮﻋﺔ ١٠٠ ﻣﻠﻐﻢ ﻓﻲ اﻟﻴﻮم ﻟﻔﺘﺮة ١٤-٢١ ﻳﻮم ﺑﺼﻮرة ﻣﺘﺘﺎﻟﻴﺔ. اﺟﺮﻳﺖ اﻟﻤﻘﺎرﻧﺔ ﺑﺎﺳﺘﻌﻤﺎل اﺧﺘﺒﺎر t ﻟﻠﻌﻴﻨﺎت اﻟﻤﺘﺮاﺑﻄﺔ. اﻟﻨﺘﺎﺋﺞ: ﻟﻢ ﻳﻈﻬﺮ ﻋﻘﺎر روﻓﻴﻜﻮآﺴﺐ او ﻋﻘﺎر داﻳﻜﻠﻮﻓﻴﻨﺎك أي ﺗﻐﻴﻴﺮ ﻣﻌﻨﻮي ﻓﻲ ﻓﺤﻮﺻﺎت اﻟﺪم اﻟﻜﺎﻣﻠﺔ ﻓﻲ اﻟﻤﺮﺿﻰ اﻟﺬآﻮر ﻋﻨﺪ ﻣﻘﺎرﻧﺘﻬﺎ ﻣﻊ ﻧﺘﺎﺋﺞ ﻓﺤﻮﺻﺎت اﻟﺪم ﻗﺒﻞ اﺧﺬ اﻟﻌﻼج. اﻻﺳﺘﻨﺘﺎج: ﻻﻳﻮﺟﺪ ﺗﺎﺛﻴﺮ ﻟﻌﻘﺎر روﻓﻴﻜﻮآﺲ او ﻋﻘﺎر داﻳﻜﻠﻮﻓﻴﻨﺎك ﻋﻠﻰ ﻓﺤﻮﺻﺎت اﻟﺪم ﻟﻠﻤﺮﺿﻰ ﻋﻨﺪ اﺳﺘﻌﻤﺎﻟﻬﺎ آﻞ ﻋﻠﻰ ﺣﺪة وﻟﻔﺘﺮة ﻗﺼﻴﺮة وﺑﺠﺮﻋﺔ ﻣﺘﻮﺳﻄﺔ. selective inhibitors offered logical ٢-COX ٢-ofecoxib is a specific cyclooxygenase inhibitor and its benifical action is choices to alliterate pain and inflammation with (٢-R (COX ٣.similar to the traditional nonsteroidal anti- fewer side effects inflammatory drugs (NSAIDs) indicating similar Diclofenac shows a high degree of anti- inflammatory, analgesic and antipyretic ١.analgesic and anti-inflammatory effects .٤.Clinical studies of rofecoxib have demonstrated activity efficacy equivalent to COX nonselective In comparison with refecoxib, diclofenac is a NSAIDs with lower rates of gastrointestinal tract potent relatively nonselective COX inhibitor in ,Clearly ٢.side effects like endoscopic ulcers Mosul College of Pharmacy 8 ٢٠٠٨ ٢٠٠٨ ,١.No ,٨&٧ .Irq J Pharm Vol addition diclofenac can reduce arachidonic acid Male patients were included, who complained ٥.bioavailability The haematological effects of traditional from simple pain like backache or joint pain. ٢١-١٤ NSAIDs induced two opposing actions, in one The duration of treatment was between hand, NSAIDs inhibited prostaglandins (PGS) days. The studied groups were divided into two patients ٢٩ mediated inhibition of cytokines there by groups. The first group included increasing stem cells and colony forming unit given rofecoxib (Inflaix, Ajanta Pharma Limited, mg/day), their ages ranged between ٢٥) ,(CFU) proliferation and differentiation, on the India) years). The ٨.٩±٣٦.٨ :years (mean±SD ٤٩-٢٩ other hand, NSAIDs inhibited PGS mediated patients given ١٥ stimulation of erythropoietin release and second group included consequently inhibiting the maturation of diclofenac sodium (voldic S.R., pharma. mg/day ١٠٠) ,(International co, Amman, Jordan ٦.erythrocyte line -٢٢ derived PGS play the potential role in sustained release), with age range between ٢-COX .(years ٦.٣±٣٥.٥ :mean±SD) ٤٤ the control of cytokines production and ml) was taken from ٢.٥) However, both Venous blood sample ٧.consequent haematopoiesi derived PGE may play a the participants by venipuncture. The blood was ٢-and COX ١-COX ml EDTA (ethylene diamine ٢.٥ placed in ٨.role in the control of erythrocyte maturation deficiency appears to inhibit the onset or tetraacetic acid) tubes. The samples were ٢-COX the rate of haematopoiesis under tension mixed well and placed on a mechanical shaker. conditions, but unlikely compromising The tests were done within the first hour after sample collection. Total white blood cell ٩.eventually full haematological recovery This study has been done to investigate the (WBC), platelets, differential WBC and effect of rofecoxib and diclofenac on complete reticulocyte counts were performed by using a Packed cell ١٢,١٣.blood picture in male patients. manual microscopic method volume (PCV) and haemoglobin (Hb) were Patients and methods measured by microhaematocrit and Drabkin's Westergren .١٢,١٣ This study was carried out in the department of solution methods, respectively .(١٤)Rheumatology and in the Haematology method was used for measurement of ESR laboratory at Al-Salam Hospital in Mosul city, under the Results ,٢٠٠٤ from January to July supervision of haematologists in the hospital. No significant changes were found in Hb Patients with rheumatological diseases or (haemoglobin), PCV (packed cell volume), post-operative pain were excluded from the reticulocyte, total and differential WBC, and study. In addition, erythrocyte sedimentation platelet count in patient treated with rofecoxib in comparison with those (٢٩-days (n ٢١-١٤ rate (ESR) test was made to exclude the for .(١ presence of other concurrent diseases. measurements before treatment ( Table ,No significant changes were found in Hb ١٠.٠ Complete blood picture was made at about ,Blood samples PCV, reticulocytes, total and differenetial WBC ١٠.a.m. to avoid diurnal variation were taken from patients while they were and platelet counts in patients treated with days in comparison with ٢١-١٤ found that diclofenac for ١١ sitting, since Penev and Kereshka .(position of patients affects complete blood these measurements before treatment (Table٢ picture. .Blood picture of rofecoxib in patients before and after treatment .١ Table Mosul College of Pharmacy 9 ٢٠٠٨ ٢٠٠٨ ,١.No ,٨&٧ .Irq J Pharm Vol (٢٩=Means±SD (n Parameters Significance Before treatment After treatment NS ١٢.٦٥±١٤٠.١٤ ١١.٢٤±١٣٦.٨٦ (Hb (g/L NS ٠.٠٤±٠.٤٣ ٠.٠٥±٠.٤٣ (%) PCV NS ٢.٠٨±٧.٠٢ ١.٩١±٧.١٠ L/١٠٩ × Total WBC cont Differential WBC count (%) NS ٨.٠٥±٦٦.١٠ ١٠.٠٦±٦٣.٦٦ Neutrophils NS ٧.٨٥±٣٠.٣١ ٩.٢٤±٣٣.٤٥ Lymphocytes NS ٠.٨٤±٠.٢٨ ١.٤٧±٠.٦٩ Monocytes NS ٣.٨٨±٣.٣١ ٣.٨٢±٢.٢١ Eosinophils L/١٠٩ Differential WBC absolute count x NS ١.٦٥±٤.٦٨ ١.٥٥±٤.٥٥ Neutrophils NS ٠.٧٤±٢.٠٨ ٠.٨٧±٢.٣٥ Lymphocytes NS ٠.٠٥±٠.٠٢ ٠.١١±٠.٠٥ Monocytes NS ٠.٣١±٠.٢٤ ٠.٢٥±٠.١٥ Eosinophils NS ٤٨.٤١±٢٤٨.٢٨ ٤٢١.٨± ٢٤٠.١٧ L/١٠٩ Platelet count x ٠.٠٥ >NS, insignificant, P .Blood picture of diclofenac patients before and after treatment .٢ Table Significance (٢٩=Parameters Means±SD (n Before treatment After treatment NS ١٠.٧٠±٧٤ .١٣٨ ١١.٢٨±١٤٠.٣٣ (Hb (g/L NS ٠.٠٣±٠.٤٢ ٠.٠٣±٠.٤٣ (%) PCV NS ٠.٧٦±٠.٧٨ ٠.٧٩±٠.٨٤ (%) Reticulocytes NS ١.٦٧±٦.٩٨ ١.٥٦±٦.٣١ L/١٠٩ × Total WBC cont Differential WBC count (%) NS ٦.٨٤±٦٢.٤٧ ٨.٣٢±٦٥.٣٣ Neutrophils NS ٧.٨٣±٣٤.٦٧ ٧.٤٠±٣١.٦٠ Lymphocytes NS ٠.٩٠±٠.٣٣ ٠.٧٢±٠.٣٣ Monocytes NS ٣.٠٧±٢.٥٣ ٢.٧١±٢.٠٧ Eosinophils L/١٠٩ Differential WBC absolute count x NS ١.١٧±٤.٣٨ ١.٢٧±٤.١٨ Neutrophils NS ٠.٧١±٢.٣٩ ٠.٦٠±١.٩٦ Lymphocytes NS ٠.٠٦±٠.٠٢ ٠.٠٥±٠.٠٢ Monocytes NS ٠.٢٥±٠.١٩ ٠.١٧±٠.١٢ Eosinophils NS ٦٨.١٢±٣١١.٣٣ ٧٥.١٨±٢٧٦.٦٧ Platelet count L/١٠٩ x ٠.٠٥>NS, insignificant, P Discussion Mosul College of Pharmacy 10 ٢٠٠٨ ٢٠٠٨ ,١.No ,٨&٧ .Irq J Pharm Vol Raskin JB. Gastrointestinal effects of non -٣ In the rofecoxib treated patients, complete blood picture was not significantly different steroidal anti-inflammatory therapy. Am J .١٢s-١٠٦:٣s ;١٩٩٩ from pretreatment values. These results are in Med .Menasse R, Hedwall PR, Kraetz J et al -٤ These ١٥,١٦.agreement with other studies authors did not find any significant effect of pharmacological properties of diclofenac short-term use of rofecoxib on complete blood sodium and its metabolites. Scand J .١٦-٢٢:٥;١٩٧٨ inhibition in vitro and Rheumatol supp ٢-picture. However, COX -Furst, munster T. Nonsteroidal anti -٥ in vivo was associated with increased WBC count in the peripheral blood including inflammatory drugs, disease- modifying antirheumatic drugs, nonopioid analgesics ٧.granulocyte, monocytes and lymphocytes Accordingly, the short duration and moderate and drug used in gout. In katzung BG eds. dose might not be enough to significantly Basic and clinical pharmacology. New York: -٢٠٠١:٦٠٢ affect the blood picture. Lang Medical booked McGraw-Hill .٦٠٧ In this study, complete blood picture was not Kozubik A, Pospisil M, Viklicka S et al. Effect -٦ significantly different in diclofenac treated patients in comparison with the pretreatment of indomethacin on the proliferative and values. These results were in agreement with differentiation activity in the haemopoietic found that system of lethally irradiated mice after ١٧.Emery et al ١٧,١٨.other studies the haematological effect of diclofenac syngeneic bone marrow transplantation. .٤١٨٤٢٣ :٣٣;١٩٨٧ required long term use. Moreover, Hofer et Folia Biol .Hartel C, Puttkamer JV, Gallner F et al -٧ found that the effect of diclofenac on ١٩.al blood required the use of toxic doses.
Load more

Recommended publications
  • Rofecoxib Versus Ibuprofen for Acute Treatment of Migraine: a Randomised Placebo Controlled Trial U K Misra, M Jose, J Kalita
    720 Postgrad Med J: first published as 10.1136/pgmj.2003.017160 on 3 December 2004. Downloaded from ORIGINAL ARTICLE Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial U K Misra, M Jose, J Kalita ............................................................................................................................... Postgrad Med J 2004;80:720–723. doi: 10.1136/pgmj.2003.012393 Background: Rofecoxib is a potent cyclo-oxygenase-2 inhibitor with a long duration of action. Its role in migraine has not been systematically evaluated. Aim: To study the efficacy of rofecoxib in migraine. Method: In a randomised placebo controlled trial rofecoxib 25 mg, ibuprofen 400 mg, and placebo were compared regarding their efficacy in relieving acute migraine attack. Migraine patients with 2–6 attacks per month were recruited. Headache severity, functional disability, and severity of associated symptoms were graded on a 0–3 scale. The primary endpoint was pain relief at two hours. Relief of associated symptoms and sustained pain relief for 24 hours were also noted. See end of article for Result: One hundred and twenty four patients were randomised into rofecoxib (42), ibuprofen (40), and authors’ affiliations placebo (42) groups. One hundred and one patients were followed up: 33 on rofecoxib, 35 ibuprofen, ....................... and 33 placebo. Patients’ ages ranged from 16–62 (mean 31.4) years, and 83 were females. Pain relief Correspondence to: at two hours was noted in 45.5% on rofecoxib, 55.6% on ibuprofen, and 9.1% in the placebo group. The Professor Usha Kant Misra, associated symptoms at two hours were reduced in 39.4% on rofecoxib, 50% on ibuprofen, and 9.1% in Department of Neurology, the placebo group.
    [Show full text]
  • Studies on the Cardiovascular Effects of Selective COX-2 Inhibitors Show Mixed Results
    Review: studies on the cardiovascular effects of Evid Based Med: first published as 10.1136/ebm.7.2.49 on 1 March 2002. Downloaded from selective COX-2 inhibitors show mixed results Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 Aug 22/29;286:954–9. QUESTION: In patients with arthritis, do rofecoxib or celecoxib increase the risk for cardiovascular events? Data sources increase 138%, 95% CI 39 to 300; number needed to Studies were identified by searching Medline (1998 to harm 146, CI 69 to 517}*. The Celecoxib Long-term February 2001) and the internet. The Adverse Events Arthritis Safety Study (CLASS) compared celecoxib 400 Reporting System was searched for US events on Octo- mg twice daily; ibuprofen 800 mg 3 times daily; and ber 12, 2000. diclofenac 75 mg twice daily, in 8059 patients with osteoarthritis or rheumatoid arthritis. Patients were Study selection allowed to take aspirin ( < 325 mg/day). Celecoxib and English language studies were selected if they were ran- non-steroidal anti-inflammatory drugs did not differ for domised, double blind, controlled trials reporting the cardiovascular event rates. 2 studies compared rofecoxib cardiovascular effects of celecoxib or rofecoxib. 12.5 mg/day; nabumetone 1000 mg/day; and placebo for 6 weeks in 1042 and 978 patients with osteoarthritis Data extraction of the knee. Patients were allowed to take low dose aspi- Data were extracted on study methods, patient charac- rin. In both studies, the groups did not differ for cardio- teristics, drug regimens, aspirin use, and cardiovascular vascular event rates.
    [Show full text]
  • Nonsteroidal Antiinflammatory Drugs Inhibiting Prostanoid Efflux: As Easy As ABC?
    Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: As easy as ABC? Timothy D. Warner*† and Jane A. Mitchell‡ *The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, United Kingdom; and ‡National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, United Kingdom onsteroidal antiinflammatory may explain its antinociceptive proper- resistance proteins (MRP) form a sub- drugs (NSAIDs) and prosta- ties (7). Others have found therapeutic family within the ABC transporters. noids continue to be fascinat- effects of NSAID metabolites that are MRP1 is a high-affinity leukotriene C4 N ing research targets. Humans inactive on COX; sulindac sulfone is a transporter, and mice that harbor dele- have been using NSAIDs in one form or clear example. The NSAID sulindac is tions of this gene have an altered re- another, from folk remedies through to an inactive drug metabolized to a phar- sponse to inflammatory stimuli but are the products of modern pharmaceutical macologically active sulfide derivative, otherwise healthy and fertile. MRP2 is research, for thousands of years. How- which potently inhibits COX. Sulindac is the major transporter responsible for ever, we still have not characterized all also metabolized to a sulfone derivative the secretion of bilirubin glucuronides of the systems through which these that is inactive against COX. However, into bile (11). MRP1 and -4 may also be drugs produce their beneficial and like sulindac sulfide, sulindac sulfone involved in the transport of dehydroepi- harmful effects (1, 2). We are certain, both promotes cellular apoptosis and androsterone 3-sulfate (the most abun- from seminal work carried out in the dant circulating steroid in humans), and 1960s and early 1970s, that NSAIDs MRP4 transports conjugated steroids have the common property of inhibiting Some NSAIDs and bile acids (12).
    [Show full text]
  • Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti- Inflammatory Drugs: a Systematic Review
    J Pharm Pharm Sci (www.cspsCanada.org) 21, 48s – 73s, 2018 Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti- Inflammatory Drugs: A Systematic Review Zuhair Alqahtani and Fakhreddin Jamali Faculty of Pharmacy and Pharmaceutical Science, University of Alberta, Edmonton, Alberta, Canada. Received, March 16, 2018; Revised, March 30, 2018; Accepted, April 25, 2018; Published, April 27, 2018. ABSTRACT - Purpose: Concomitant use of some non-Aspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) reduces the extent of platelet aggregation of Aspirin (acetylsalicylic acid). This is while many observational studies and clinical trials suggest that Aspirin reduces cardiovascular (CV) risk attributed to the use of NANSAIDs. Thus, the therapeutic outcome of the interaction needs to be assessed. Methods: We searched various databases up to October 2017 for molecular interaction studies between the drugs and long-term clinical outcomes based on randomized clinical trials and epidemiological observations that reported the effect estimates of CV risks (OR, RR or HR; 95% CI) of the interacting drugs alone or in combinations. Comparisons were made between outcomes after Aspirin alone, NANSAIDs alone and Aspirin with naproxen, ibuprofen, celecoxib, meloxicam, diclofenac or rofecoxib. Results: In total, 32 eligible studies (20 molecular interactions studies and 12 observational trials) were found. Conflicting in vitro/in vivo/ex vivo platelet aggregation data were found for ibuprofen, naproxen and celecoxib. Nevertheless, for naproxen, the interaction at the aggregation level did not amount to a loss of cardioprotective effects of Aspirin. Similarly, for ibuprofen, the results overwhelmingly suggest no negative clinical CV outcomes following the combination therapy. Meloxicam and rofecoxib neither interacted with Aspirin at the level of platelet aggregation nor altered clinical outcomes.
    [Show full text]
  • VIOXX® (Rofecoxib Tablets and Oral Suspension)
    VIOXX® (rofecoxib tablets and oral suspension) WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS). VIOXX is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS, WARNINGS). Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. (see WARNINGS). DESCRIPTION VIOXX® (rofecoxib) is a nonsteroidal anti-inflammatory drug (NSAID). The chemical name is 4-[4­ (methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone. The molecular weight is 314.36. The empirical formula for rofecoxib is C17H14O4S, and it has the following chemical structure: O O O S H C 3 O Rofecoxib is a white to off-white to light yellow powder. It is sparingly soluble in acetone, slightly soluble in methanol and isopropyl acetate, very slightly soluble in ethanol, practically insoluble in octanol, and insoluble in water. Each tablet of VIOXX for oral administration contains either 12.5 mg, 25 mg, or 50 mg of rofecoxib and the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline cellulose, and yellow ferric oxide.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • Metabolic Profiling of Murine Plasma Reveals an Unexpected Biomarker In
    Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events Jun-Yan Liua, Ning Lib, Jun Yanga, Nan Lic, Hong Qiub, Ding Aia,c, Nipavan Chiamvimonvatb, Yi Zhuc, and Bruce D. Hammocka,1 aDepartment of Entomology and University of California-Davis Cancer Center and bDivision of Cardiovascular Medicine, University of California, Davis, CA 95616; and cDepartment of Physiology, Beijing University, Beijing 100083, People’s Republic of China Contributed by Bruce D. Hammock, August 6, 2010 (sent for review June 16, 2010) Chronic administration of high levels of selective COX-2 inhibitors infarction (MI), hypertension, and heart failure has also been ob- (coxibs), particularly rofecoxib, valdecoxib, and parecoxib, increases served to be associated with the administration of the nonaspirin risk for cardiovascular disease. Understanding the possibly multiple conventional NSAIDs, including but not limited to diclofenac, mechanisms underlying these adverse cardiovascular events is critical ibuprofen, naproxen, and indomethacin (8–12). In addition, there for evaluating the risks and benefits of coxibs and for development of could be rofecoxib-specific events such as the facile formation of safer coxibs. The current understanding of these mechanisms is likely a cardiotoxic maleic anhydride derivative from rofecoxib that may incomplete. Using a metabolomics approach, we demonstrate that contribute to its adverse effects (13). This hypothesis fails to ex- oral administration of rofecoxib for 3 mo results in a greater than 120- plain the increased risk in the cardiovascular system from other fold higher blood level of 20-hydroxyeicosatetraenoic acid (20-HETE), nonaspirin NSAIDs. Thus, current mechanisms provide an in- fi which correlates with a signi cantly shorter tail bleeding time in complete explanation for cardiovascular problems associated with a murine model.
    [Show full text]
  • Aspirin and Other Anti-Inflammatory Drugs
    Thorax 2000;55 (Suppl 2):S3–S9 S3 Aspirin and other anti-inflammatory drugs Thorax: first published as 10.1136/thorax.55.suppl_2.S3 on 1 October 2000. Downloaded from Sir John Vane Historical introduction inhibiting COX, thereby reducing prosta- Salicylic acid, the active substance in plants glandin formation, providing a unifying expla- used for thousands of years as medicaments, nation for their therapeutic actions and their was synthesised by Kolbe in Germany in 1874. side eVects. This also firmly established certain MacLagan1 and Stricker2 showed that it was prostaglandins as important mediators of eVective in rheumatic fever. A few years later inflammatory disease (see reviews by Vane and sodium salicylate was also in use as a treatment Botting7 and Vane et al8). COX first cyclises for chronic rheumatoid arthritis and gout as arachidonic acid to form prostaglandin (PG) well as an antiseptic compound. G2 and the peroxidase part of the enzyme then Felix HoVman was a young chemist working reduces PGG2 to PGH2. at Bayer. Legend has it that his father, who was taking salicylic acid to treat his arthritis, Discovery of COX-2 complained to his son about its bitter taste. Over the next 20 years several groups postu- Felix responded by adding an acetyl group to lated the existence of isoforms of COX. Then salicylic acid to make acetylsalicylic acid. Rosen et al,9 studying COX in epithelial cells Heinrich Dreser, the Company’s head of phar- from the trachea, found an increase in activity macology, showed it to be analgesic, anti- of COX during prolonged cell culture.
    [Show full text]
  • Ketorolac Tromethamine Injection, USP
    PRODUCT MONOGRAPH Pr Ketorolac Tromethamine Injection, USP 30 mg / mL single-dose vials 30 mg / mL in SimplistTM prefilled single use syringes For Intramuscular Administration Non-Steroidal Anti-Inflammatory Analgesic Agent Fresenius Kabi Canada Ltd. Date of Revision: 165 Galaxy Blvd, Suite 100 July 18, 2019 Toronto, ON M9W 0C8 Submission Control No.: 227928 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ................................................................................3 INDICATIONS AND CLINICAL USE .....................................................................................3 CONTRAINDICATIONS ...........................................................................................................4 WARNINGS AND PRECAUTIONS .........................................................................................5 ADVERSE REACTIONS .........................................................................................................14 DRUG INTERACTIONS..........................................................................................................16 DOSAGE AND ADMINISTRATION .....................................................................................18 OVERDOSAGE ........................................................................................................................22 ACTION AND CLINICAL PHARMACOLOGY ....................................................................23 STORAGE
    [Show full text]
  • Acute Congestive Heart Failure Induced by Rofecoxib
    J Am Board Fam Pract: first published as 10.3122/jabfm.17.2.131 on 13 April 2004. Downloaded from Acute Congestive Heart Failure Induced by Rofecoxib Robert J. Campbell, MD, and Kevin B. Sneed, PharmD Nonsteroidal anti-inflammatory drugs (NSAIDs) COX-1 in the stomach is believed to have protec- are routinely prescribed for the treatment of vari- tive properties of the gastric mucosa.12,13 COX-2 is ous conditions requiring analgesia and anti-inflam- expressed in response to inflammatory stimuli, and matory activity. People also have access to NSAIDs is affected by cytokines and other inflammatory over-the-counter for relief of mild aches, pains, and mediators. Most NSAIDs inhibit both isoforms to headaches. NSAIDs have the potential to produce varying degrees, relative to the activity of the indi- several adverse effects in patients. They are known vidual chemical properties of the NSAID. In recent to have the potential to produce gastrointestinal years, COX-2 specific inhibitors have become toxicities leading to dyspepsia or even ulceration. available [celecoxib, rofecoxib, valdecoxib (in order Gastrointestinal symptoms are the most common of US market release)]. It had been hypothesized adverse effects associated with NSAID use.1 Plate- that by targeting the COX-2 enzyme specifically, let aggregation is known to be inhibited by only the inflammatory prostaglandins would be in- NSAIDs because of their ability to inhibit the ac- hibited while sparing the activity of COX-1. This tion of thromboxane A, a potent platelet aggrega- would allow the medication to produce anti- tor.2–4 This could lead to hemorrhaging in patients inflammatory and analgesia activities without po- with vascular injuries or congenital hematologic tentially decreasing the protective effects of the conditions.
    [Show full text]
  • Ketorolac Tromethamine Injection Usp
    PRODUCT MONOGRAPH PrKETOROLAC TROMETHAMINE INJECTION USP (Ketorolac Tromethamine) Sterile Solution 30 mg/mL Non-Steroidal Anti-Inflammatory Drug (NSAID) Pfizer Canada Inc. Date of Revision: 17300 Trans-Canada Highway December 1, 2017 Kirkland, Québec H9J 2M5 Submission Control No: 209949 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................14 DRUG INTERACTIONS ..................................................................................................17 DOSAGE AND ADMINISTRATION ..............................................................................19 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................24 DOSAGE FORMS, COMPOSITION AND PACKAGING
    [Show full text]
  • COX-2 Selective Non-Steroidal Anti-Inflammatory Drugs For
    Health Technology Assessment Health Technology Health Technology Assessment 2008; Vol. 12: No. 11 2008; 12: No. 11 Vol. selective non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis COX-2 Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Feedback The HTA Programme and the authors would like to know Y-F Chen, P Jobanputra, P Barton, S Bryan, your views about this report. The Correspondence Page on the HTA website A Fry-Smith, G Harris and RS Taylor (http://www.hta.ac.uk) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website. We look forward to hearing from you. April 2008 The National Coordinating Centre for Health Technology Assessment, Mailpoint 728, Boldrewood, Health Technology Assessment University of Southampton, NHS R&D HTA Programme Southampton, SO16 7PX, UK. HTA Fax: +44 (0) 23 8059 5639 Email: [email protected] www.hta.ac.uk http://www.hta.ac.uk ISSN 1366-5278 HTA How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below). Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.
    [Show full text]